This is a process that would have taken, in some cases, years, and we did it in a matter of months, says the U.S. President
U.S. President Donald Trump has announced that the vaccine for coronavirus being developed by AstraZeneca has reached phase three clinical trials in the country and is very close to being finalised for approval. The phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by the US Health and Human Services, which aims at accelerating the development and manufacturing of medical countermeasures for COVID-19 and delivering 300 million doses of an effective vaccine by January 2021. Watch | Oxford’s COVID-19 vaccine shows positive results“I am pleased to announce that AstraZeneca vaccine has reached phase three clinical trials,” Mr. Trump told reporters at the White House on Monday. Coronavirus | India has key vaccine role: Anthony Fauci“That’s joining another group of vaccines that are very close to the end, and hopefully, approval,” he added. AstraZeneca is one of the leaders in the race to develop COVID-19 vaccine. Other companies that have COVID-19 vaccines in phase 3 trials include Moderna Inc and Pfizer Inc.“In the United States, we’re doing things that nobody thought would have been even possible. This is a process that would have taken, in some cases, years, and we did it in a matter of months,” Mr. Trump said.Also read: Also read: Pune firm to make billion doses of Oxford vaccine The National Institute of Health separately announced that Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222 will enroll approximately 30,000 adult volunteers at 80 sites in the US to evaluate if the candidate vaccine can prevent symptomatic COVID-19. The UK-based global biopharmaceutical company AstraZeneca is leading the trial as regulatory sponsor. “Safe and effective vaccines will be essential to meet the global need for widespread protection against COVID-19,” said National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S Fauci.Also read: Russian COVID-19 vaccine | Sputnik V is safe and effective, says RDIF CEO“Positive results from preclinical research led by NIH scientists supported the rapid development of this vaccine candidate, which has also showed promise in early-stage clinical trials,” he said. Oxford University’s Jenner Institute and Oxford Vaccine Group have developed AZD1222. The candidate vaccine was licensed to AstraZeneca for further development. Mr. Trump told reporters that the US remains on track to deliver a vaccine very rapidly in record time.Also read; Coronavirus | China administering COVID-19 vaccines since July, says official“Over the last month, new cases in the United States have declined by 38 per cent. Last week, we announced a breakthrough in testing that will allow us to have over 150 million rapid, point-of-care tests. These tests return results in less than 15 minutes, and many will be deployed to nursing homes,” he said. “We’re focusing very strongly on nursing homes, assisted living facilities and other locations that serve high-risk populations. So we’re going to have the 15-minute, and less, tests, and we will have 150 million rapid point-of-care tests,” Mr. Trump said. The U.S. has so far recorded 6,030,782 coronavirus cases and 183,596 fatalities — both the numbers highest in the world.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.
Move smoothly between articles as our pages load instantly.
Enjoy reading as many articles as you wish without any limitations.
A one-stop-shop for seeing the latest updates, and managing your preferences.
A select list of articles that match your interests and tastes.
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.